FR Doc 04-14311

[Federal Register: June 24, 2004 (Volume 69, Number 121)]
[Notices]
[Page 35351-35356]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jn04-75]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Early Screening and Diagnosis of Duchenne Muscular Dystrophy

Announcement Type: New.
Funding Opportunity Number: PA 04216.
Catalog of Federal Domestic Assistance Number: 93.283.
Dates: Letter of Intent Deadline: July 14, 2004.
Application Deadline: August 9, 2004.

I. Funding Opportunity Description

Authority: This program is authorized under Sections 317 (k)(2)(42
U.S.C. section 247b(k)(2)) and sections 311 and 317(C) of the Public
Health Service Act [42 U.S.C. 241, 243, and 247b-4 as amended].
Purpose and Research Objectives: The purpose of the program is to
develop, implement and evaluate creatine kinase-based screening
programs for the early detection of Duchenne Muscular Dystrophy (DMD)
during the newborn period (part A) and during infancy (part B). This
program addresses the ``Healthy People 2010'' focus area of Disability
and Secondary Conditions. Measurable outcomes of the program will be in
alignment with the following performance goal for the National Center
on Birth Defects and Developmental Disabilities: To improve the health
and quality of life of Americans with disabilities.
DMD is the most common form of muscular dystrophy in children. It
causes progressive muscle deterioration, leading to the inability to
walk around the age of 12 years, and death in the teens or early 20s,
most commonly due to severe respiratory or heart problems, or both. The
gene for DMD is on the X chromosome so DMD affects males almost
exclusively. In the absence of newborn screening, DMD is usually
diagnosed when a child is three to six years of age. DMD does not meet
the traditional criteria for inclusion in routine newborn screening
panels in the United States, because there is insufficient evidence
that early detection and intervention leads to an improved medical
outcome for children with DMD. However, an earlier age of diagnosis has
potential non-medical benefits to the family, including knowledge of
recurrence risk, avoidance of a long diagnostic process, and more time
for financial and other planning related to raising a child with a
disabling condition. In addition, earlier age at diagnosis will offer
more opportunity to study the potential medical benefits of earlier
treatments. In several countries, families are offered newborn
screening for DMD based on creatine kinase activity in dried
bloodspots.
Two approaches to screening have been employed; screening after
birth and screening at 6-12 months of age. Sensitivity, specificity,
and other characteristics of the screen are dependent on the age of
screening, the particular assay utilized, and cut-off levels used. DMD
screening offered to parents of male neonates, with informed consent
and in conjunction with existing routine newborn screening systems, is
one potential approach to decreasing the age of diagnosis in the United
States. However, complications of this approach include the difficulty
in obtaining uniform and informed consent (contingent on promoting
complete understanding by parents of genetic and outcome factors)
during the prenatal or immediate neonatal period, and the potential
impact of test results on parent-infant bonding.
A second potential approach is to offer screening to families of
male infants (6 to 12 months) through pediatric health care services.
This approach offers more time for informed consent, but a major
complication is disparities in access to pediatric health care.
Both approaches require well-planned protocols for follow-up of
positive screening results. The purpose of this cooperative agreement
is to develop, implement and evaluate early screening

[[Page 35352]]

programs in both neonates (part A) and infants (part B) in order to:
(a) Assess the feasibility of early screening for DMD; (b) identify
challenges related to each approach; and (c) evaluate the risks and
benefits of each approach.
Activities: Applicants may apply for funding under part A and/or
part B. Please note that if applicants choose to apply for both part A
and part B, separate applications are required. There is no provision
which allows the submission of consolidated applications addressing the
requirements of both part A and part B under one application.
Awardee activities for part A of this program are as follows:
Develop, implement and evaluate laboratory protocols for
DMD newborn screening based on creatine kinase activity levels in dried
blood spots of male newborns. The evaluation component should include
determination of sensitivity, specificity, negative predictive value
and positive predictive value of the screening methodology in the
newborn period.
Develop, implement, and evaluate protocols for informed
consent, follow-up of positive screening results, diagnostic testing,
and referral to clinical care. The evaluation component should include
assessments of (1) parental understanding of informed consent, (2)
factors that influence the entire process for screening, (3) factors
that influence loss to follow-up, (4) acceptability of screening to
parents and health care providers, (5) impact of transient positive
screening results on families, (6) attitudes of diagnosed families
toward the screening and diagnostic process, (7) attitudes of transient
positive and true negative families (both screen-negative and DMD not
present) toward the screening process, (8) assessments of other
potential risks and benefits of newborn screening for DMD, and (9) the
overall economic costs of screening.
Awardee activities for part B of this program are as follows:
Develop, implement and evaluate laboratory protocols for
DMD infant screening based on creatine kinase activity levels in dried
blood spots or other suitable biologic specimens from male infants. The
evaluation component should include determination of sensitivity,
specificity, and positive predictive value of screening methodology in
infancy (6-12 months).
Develop, implement, and evaluate protocols for informed
consent, follow-up of positive screening results, diagnostic testing,
and referral to clinical care. The evaluation component should include
assessments of (1) factors that influence access to and uptake of
infant screening, (2) parental understanding of informed consent, (3)
factors that influence loss to follow-up, (4) acceptability of
screening to parents and health care professionals, (5) impact of
transient positive screening results on families, (6) attitudes of
diagnosed families toward the screening and diagnostic process, (7)
attitudes of transient positive and true negative families toward the
screening process, (8) assessments of other potential risks and
benefits of infant screening for DMD, and (9) the overall economic
costs of screening.
CDC Responsibilities: In a cooperative agreement, CDC staff is
substantially involved in the program activities, above and beyond
routine grant monitoring. In this cooperative agreement, a CDC
Scientist (Scientific Liaison) within the National Center on Birth
Defects and Developmental Disabilities (NCBDDD) is an equal partner
with scientific and programmatic involvement during the conduct of the
project through technical assistance, advice, and coordination. The
Scientific Liaison will:
1. Participate in the development of the protocol.
2. Participate in the analysis, interpretation, and reporting of
findings in the scientific literature and other media to the community
at large and the public policy community within the Federal government.
3. Participate in data management, analysis of data, and
interpretation and dissemination of findings.
4. Provide scientific consultation and technical assistance in the
design and conduct of the project, including protocol adherence,
outcome measures, and analytical approaches in participation with the
recipient organization.

CDC Scientific Program Administrator (SPA)

The CDC NCBDDD will appoint an SPA, apart from the NCBDDD
Scientific Liaison who will:
1. Serve as the Program Official for the funded research
institutions.
2. Carry out continuous review of all scientific and administrative
activities to ensure objectives are being met.
3. Attend Coordination Committee meetings for purposes of assessing
overall progress and for program evaluation purposes.
4. Provide scientific consultation and technical assistance in the
conduct of the project as requested.
5. Conduct site visits to recipient institutions to determine the
adequacy of the research and to monitor performance against approved
project objectives.

Collaborative Responsibilities

The planning and implementation of the cooperative aspects of the
study will be effected by a Coordination Committee consisting of the
Principal Investigator from the participating institution(s) and the
CDC Scientific Liaison. This Coordinating Committee will formulate a
plan for cooperative research.
At periodic coordination committee meetings, the group will: (1)
Make recommendations on the study protocol and data collection
approaches; (2) discuss the target populations that have been or will
be recruited; (3) identify and recommend solutions to unexpected study
problems; and (4) discuss ways to efficiently coordinate study
activities and best practices.

II. Award Information

Part A. DMD During the Newborn Period

Type of Award: Cooperative Agreement.
CDC involvement in this program is listed in the Activities section
above.
Fiscal Year Funds: 2004.
Approximate Total Funding: $250,000.
Approximate Number of Awards: One.
Approximate Average Award: $250,000 (this amount is for the first
12-month budget period, and includes both direct and indirect costs).
Floor of Award Range: None.
Ceiling of Award: None.
Anticipated Award Date: September 1, 2004.
Budget Period Length: 12 months.
Project Period Length: Three years. Throughout the project period,
CDC's commitment to continuation of awards will be conditioned on the
availability of funds, evidence of satisfactory progress by the
recipient (as documented in required reports), and the determination
that continued funding is in the best interest of the Federal
government.

Part B. DMD During the Infancy Period

[[Page 35353]]

Floor of Award Range: None.
Ceiling of Award: None.
Anticipated Award Date: September 1, 2004.
Budget Period Length: 12 months.
Project Period Length: Three years. Throughout the project period,
CDC's commitment to continuation of awards will be conditioned on the
availability of funds, evidence of satisfactory progress by the
recipient (as documented in required reports), and the determination
that continued funding is in the best interest of the Federal
government.

III. Eligibility Information

III.1. Eligible Applicants

Applications may be submitted by public and private non-profit
organizations and by governments and their agencies, such as:
Public non-profit organizations
Private non-profit organizations
Universities
Colleges
Non-profit Research Institutions and Hospitals
State and local governments or their bona fide agents
(this includes the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, the Commonwealth of the Northern Marianna
Islands, American Samoa, Guam, the Federated States of Micronesia, the
Republic of the Marshall Islands, and the Republic of Palau)
Political subdivisions of States (in consultation with
States)
A bona fide agent is an agency/organization identified by the state
as eligible to submit an application under the state eligibility in
lieu of a state application. If you are applying as a bona fide agent
of a state or local government, you must provide a letter from the
state as documentation of your status. Place this documentation behind
the first page of the application form.

III.2. Cost Sharing or Matching

Matching funds are not required for this program.

III.3. Other

If your application is incomplete or non-responsive to the
requirements listed below, it will not be entered into the review
process. You will be notified that your application did not meet
submission requirements.
Applicants must document their present infrastructure, capacity,
expertise, and experience (within organization or within organizations
of collaborators) in conducting population-based newborn or infant
screening and follow-up for genetic diseases.
Applicants must provide specific evidence to substantiate this
capacity, experience, and expertise. Through documentation of two pages
in length, applicants must provide specific evidence that they can
fully meet these eligibility criteria in order to be considered for
formal review. This information must be included as part of the
application and inserted immediately after the Face Page of the
application.
Individuals Eligible to Become Principal Investigators: Any
individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from under-represented
racial and ethnic groups as well as individuals with disabilities are
always encouraged to apply for CDC programs.

Note: Title 2 of the United States Code section 1611 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.

IV. Application and Submission Information

IV.1. Address To Request Application Package

To apply for this funding opportunity, use application form PHS 398
(OMB number 0925-0001 rev. 5/2001). Forms and instructions are
available in an interactive format on the CDC Web site, at the
following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.

Forms and instructions are also available in an interactive format
on the National Institutes of Health (NIH) web site at the following
Internet address: http://grants.nih.gov/grants/funding/phs398/phs398.html
.

If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: (770) 488-2700. Application forms can be mailed to
you.

IV.2. Content and Form of Application Submission

Letter of Intent (LOI): The LOI must be written in the following
format:
Maximum number of pages: Two
Font size: 12-point unreduced
Paper size: 8.5 by 11 inches
Page margin size: One-inch margins
Printed only on one side of page
Single-spaced
Written in plain language; avoiding jargon
The LOI must contain the following information: Name, address, and
telephone number of the proposed Principal Investigator, number and
title of this program announcement, intent to apply under part A or
part B or both, names of other key personnel, designations of
collaborating institutions and entities, and an outline of the proposed
work, recruitment approach, and expected outcomes.
Application: Follow the PHS 398 application instructions for
content and formatting of your application. For further assistance with
the PHS 398 application form, contact PGO-TIM staff at (770) 488-2700,
or contact GrantsInfo, Telephone (301) 435-0714, e-mail:
GrantsInfo@nih.gov.
You must submit a signed original and five copies of your
application form. The PHS 398 grant application form requires the
applicant to enter the project title on page 1 (Form AA, ``Face Page'')
and the project description (abstract on page 2).
The main body of the application should not exceed 25 single-spaced
pages. This narrative research plan should address activities to be
conducted over the entire project period.
Additional information may be included in the application
appendices. The appendices will not be counted toward the narrative
page limit. This additional information may include curriculum vitae
and resumes for key project staff, organizational charts, graphic
workplan/time charts, letters of commitment, etc.; and should be
limited to those items relevant to the requirements of this
announcement.
Applicants must include a graphic work plan (which may be placed in
the appendices) that outlines major project goals and objectives with
timelines established for each calendar quarter covering the entire
project period.
All material must be typewritten, with 10 characters per inch type
(12 point) on 8\1/2\ by 11 inch white paper with one-inch margins, no
headers or footers (except for applicant-produced forms such as
organizational charts, c. vitae, graphs and tables, etc.). Applications
must be held together only by rubber bands or metal clips, and not
bound together in any way (including attachments/appendices).
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. Your DUNS number must be entered
on line 11 of the face page of the PHS 398 application form. The DUNS
number is a nine-digit identification number, which uniquely

[[Page 35354]]

identifies business entities. Obtaining a DUNS number is easy and there
is no charge. To obtain a DUNS number, access http://www.dunandbradstreet.com
or call 1-866-705-5711.

For more information, see the CDC Web site at: http://www.cdc.gov/od/pgo/funding/pubcommt.htm
.

Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''

IV.3. Submission Dates and Time

Letter of Intent (LOI) Deadline Date: July 14, 2004.
CDC requests that you send an LOI if you intend to apply for this
program. Although the LOI is not required, not binding, and does not
enter into the review of your subsequent application, the LOI will be
used to gauge the level of interest in this program, and will allow CDC
to plan the application review. LOI should include intent to apply
under part A or part B or both.
Application Deadline Date: August 9, 2004.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. eastern time on the deadline
date. If you send your application by the United States Postal Service
or commercial delivery service, you must ensure that the carrier will
be able to guarantee delivery of the application by the closing date
and time. If CDC receives your application after closing due to: (1)
carrier error, when the carrier accepted the package with a guarantee
for delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carrier's guarantee. If the documentation
verifies a carrier problem, CDC will consider the application as having
been received by the deadline.
This announcement is the definitive guide on application submission
address and deadline. It supersedes information provided in the
application instructions. If your application does not meet the
deadline above, it will not be eligible for review, and will be
discarded. You will be notified that your application did not meet the
submission requirements.
CDC will not notify you upon receipt of your application. If you
have a question about the receipt of your application, first contact
your courier. If you still have a question, contact the PGO-TIM staff
at: 770-488-2700. Before calling, please wait three days after the
application deadline. This will allow time for applications to be
processed and logged.

IV.4. Intergovernmental Review of Applications

Executive Order 12372 does not apply to this program.

IV.5. Funding Restrictions

Restrictions, which must be taken into account while writing your
budget, are that project funds cannot be used to supplant other
available applicant or collaborating agency funds for construction or
for lease or purchase of facilities or space.
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement must be less than 12
months from the application due date.

IV.6. Other Submission Requirements

LOI Submission Address: Lisa T. Garbarino, Public Health Analyst,
National Center on Birth Defects and Developmental Disabilities, CDC,
1600 Clifton Road, Mailstop E-87, Atlanta, Georgia 30333. E-mail
address: lgt1@cdc.gov.
Application Submission Address: Submit the original and five copies
of your application by mail or express delivery service to: Technical
Information Management--PA 04216, CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, Georgia 30341. Applications may not be
submitted by fax or e-mail at this time.

V. Application Review Information

V.1. Criteria

You are required to provide measures of outcome and effectiveness
that will demonstrate the accomplishment of the various identified
objectives of the cooperative agreement. Measures of effectiveness must
relate to the performance goals stated in the ``Purpose'' section of
this announcement. Measures must be objective and quantitative, and
must measure the intended outcome. These measures of effectiveness must
be submitted with the application and will be an element of evaluation.
The goals of CDC-supported research are to advance the
understanding of biological, environmental, and human behavior systems;
public health delivery/intervention systems; improvement of the control
and prevention of disease and injury; and to enhance health. In the
written comments, reviewers will be asked to evaluate the application
in order to judge the likelihood that the proposed research will have a
substantial impact on the pursuit of these goals. The scientific review
group will address the applications' overall score, weighting them as
appropriate for each application. The application does not have to be
strong in all categories to be judged to have major scientific impact
and thus deserve a high priority score.
Under the evaluation criteria noted below, applicants must describe
how they will address the program components as they relate to the
Purpose and Research Objectives, and the Recipient/Awardee Activities
as cited in this Announcement.
Your application will be evaluated against the following criteria:
1. Resources and Organizational Capacity:
This includes applicant infrastructure, experience, and
capacity within its organization and/or with partners in early
screening and diagnosis programs for genetic conditions, including
genetic counseling and other appropriate follow-up activities; and to
access target populations for screening.
This indicates that based on the organizational capacity
and resources the proposed project goals and objectives will be
relevant, specific, achievable, and measurable; and can be addressed
through the proposed methods and within the established timelines.
2. Methods and Activities:
This includes that the proposed methods and activities
convincingly and comprehensively meet the intent and purpose of the
announcement.
This considers that the overall process for planning,
implementation, and evaluation is comprehensive and appropriate to
accomplish the stated goals and objectives.
This includes that: (a) The methods and activities are
feasible within programmatic and fiscal restrictions; (b) the methods
will produce accurate, valid and reliable data; (c) the potential
capacity of the research design is adequate to generate meaningful
results during the study period, the design can be replicated for
future use; and (d) adequate and appropriate plans are in place for
dissemination of findings and recommendations.
3. Project Management and Staffing:
This criteria includes whether the proposed personnel,
staff qualifications and experience and project organization are
sufficient to address the planning, operations, and management/analysis
activities of the program.
This includes the process by which the applicant will
assemble an effective

[[Page 35355]]

team and how the applicant presents specified tasks and
responsibilities to be assigned for key personnel and positions.
This includes how well the proposed approaches to meeting
proposed goals and specific objectives are convincing and likely to
achieve all objectives within the prescribed time frames.
4. Evaluation Plan: This assesses that: (a) Evaluation components
described in the announcement have been addressed in the proposal; (b)
measurable time-phased goals and objectives are included in the
proposal; and (c) the evaluation plan includes a process for evaluation
of sub-components and the entire project, including the assignment of
responsibility for ongoing review of specified components.
5. Budget Description and Justification: This includes the
comprehensiveness and adequacy of the proposed budget in relation to
program operations, collaborations, and services; and the extent to
which the budget is reasonable, clearly justified, accurate, and
consistent with the purposes of this research.
6. Protections: Does the application adequately address the
requirements of title 45 CFR part 46 for the protection of human
subjects? This criteria will not be scored; however an application can
be disapproved if the research risks are sufficiently serious and
protection against risks is so inadequate as to make the entire
application unacceptable.
7. Inclusion: Does the application adequately address the CDC
policy requirements regarding the inclusion of women, ethnic, and
racial groups in the proposed research? This includes:
a. The proposed plan for the inclusion of both sexes and racial and
ethnic minority populations for appropriate representation.
b. The proposed justification when representation is limited or
absent.
c. A statement as to whether the design of the study is adequate to
measure differences when warranted.
d. A statement as to whether the plans for recruitment and outreach
for study participants include the process of establishing partnerships
with community(ies) and recognition of mutual benefits.

V.2. Review and Selection Process

Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO), and for responsiveness by NCBDDD. Incomplete
applications and applications that are non-responsive to the
eligibility criteria will not advance through the review process.
Applicants will be notified that their application did not meet
submission requirements and will not receive further consideration.
Applications, which are complete and responsive, will be subjected
to a preliminary evaluation (triage) by a scientific review group
(Special Emphasis Panel--SEP) composed of external (non-CDC) peer
reviewers to determine if each application is of sufficient technical
and scientific merit to warrant further review by the SEP. Applications
that are determined to be non-competitive will not be considered.
Subsequent to the review meeting CDC will notify the investigator/
program director and the official signing for the applicant
organization of that determination.
Applications determined to be competitive will then be reviewed and
scored under the formal SEP peer review process. The review of these
fully competitive applications will result in the determination of the
score and ranking for those applications.
Subsequent to the formal peer review of all competitive
applications by the SEP a second level of review will be conducted by
senior CDC program staff. This review will not revisit the scientific
merit of the applications, but will evaluate the overall budget
implications of the applications against funding ceilings and may not
make recommendations as to the final ordering of the top ranked
applications for part A and part B, they may not actually change the
ranking order (or scores). It is possible that the second level of
review may recommend funding the highest ranked proposal under part A
(or part B) and also funding that same organization under its
application for the other part of the announcement. That could occur in
the event that an organization with the highest ranking in one part
ranks among the highest three applicants in the other part. This would
be done to take into account economies of scale and establish the
capacity to conduct non-redundant programs to best meet the purposes of
this announcement. In such a case, the total approved budget may be
less than the sum of the two applications due to staff time commitment
duplications and other considerations.

V.3. Anticipated Award Date

September 1, 2004.

VI. Award Administration Information

VI.1. Award Notices

If your application is to be funded, you will receive a Notice of
Grant Award (NGA) from the CDC Procurement and Grants Office. The NGA
shall be the only binding, authorizing document between the recipient
and CDC. The NGA will be signed by an authorized Grants Management
Officer, and mailed to the recipient fiscal officer identified in the
application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.

VI.2. Administrative and National Policy Requirements

45 CFR Parts 74 and 92
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.

The following additional requirements apply to this project:
AR-1 Human Subjects Requirements
AR-2 Requirement for Inclusion of Women and Racial and
Ethnic Minorities in Research
AR-10 Smoke-Free Workplace Requirements
AR-11 Healthy People 2010
AR-12 Lobbying Restrictions
AR-14 Accounting Systems Requirements
AR-15 Proof of Non-Profit Status
AR-22 Research Integrity
AR-25 Release and Sharing of Data
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.

VI.3. Reporting Requirements

You must provide CDC with an original, plus two copies of the
following reports:
Interim progress report, (PHS 2590, OMB Number 0925-0001, rev. 5/
2001), on a date to be determined for your project for each subsequent
budget year. The progress report will serve as your non-competing
continuation application, and must contain the following elements:
a. Current Budget Period Activities and Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activities and Objectives.
d. Budget.
e. Additional Requested Information.
f. Measures of Effectiveness.
2. Financial status report and annual report, no more than 90 days
after the end of the budget period.
3. Final financial and performance reports, no more than 90 days
after the

[[Page 35356]]

end of the project period. These reports must be sent to the Grants
Management Specialist listed in the ``Agency Contacts'' section of this
announcement.

VII. Agency Contacts

For general questions about this announcement, contact: Technical
Information Management Section (PGO-TIM), CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta, Georgia 30341, Telephone: (770)
488-2700.
For program technical assistance, contact: Lisa T. Garbarino,
Public Health Analyst, National Center on Birth Defects and
Developmental Disabilities, CDC, 1600 Clifton Road, Mailstop E-87,
Atlanta, Georgia 30333. E-mail address: lgt1@cdc.gov. Telephone: (404)
498-3979.
For budget assistance, contact: Sylvia Dawson, Grants Management
Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road,
Atlanta, Georgia 30341. Telephone: (770) 488-2771. E-mail:
snd8@cdc.gov.

Dated: June 18, 2004.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 04-14311 Filed 6-23-04; 8:45 am]

BILLING CODE 4163-18-P